Archeus Technologies and Wisconsin Alumni Research Foundation Partner to Advance Radiopharmaceutical Therapy ART-101 into Clinical Development for Prostate Cancer
ART-101 was discovered and developed at the Advanced Radiotheranostics Lab at UW–Madison, led by Dr. Reinier Hernandez, assistant professor of medical physics at the University of Wisconsin School of Medicine and Public Health. Aided by robust support from WARF through the WARF Accelerator, ART-101 has demonstrated enhanced pharmacology in preclinical studies, including significantly higher tumor uptake and retention relative to FDA-approved prostate cancer treatment Pluvicto ® (177Lu-PSMA-617). It has also shown superior pharmacokinetics, dosimetry and normal tissue toxicity profiles.
Through a collaboration agreement with WARF, Archeus Technologies will lead Phase 1 clinical development of this asset with trial initiation planned for 2025. ART-101 is a next-generation prostate-specific membrane antigen (PSMA)-targeting small molecule. It is being evaluated as a radiopharmaceutical agent with the potential to deliver alpha-emitting isotopes with greater tolerability compared with current standards of care.
'With strong preclinical data supporting the continued development of ART-101, Archeus is eager to lead the evaluation of this novel candidate through first-in-human studies,' said Evan Sengbusch, Ph.D., chief executive officer of Archeus Technologies. 'Leveraging our team's proven experience ushering new radiopharmaceutical agents from concept through clinical translation, paired with our close collaboration with UW as a world-class radiopharmaceutical research organization, Archeus is uniquely positioned to progress ART-101 into the next stage of development. This asset adds to our Phase 1-ready portfolio of differentiated radiopharmaceutical therapies with the potential to provide curative responses to cancers that are particularly challenging to treat.'
'WARF is committed to investing in cutting-edge technologies and therapeutic candidates, like ART-101, that have significant potential to advance the theranostics landscape as well as treatment options for patients in need,' said Jeanine Burmania, senior director of intellectual property and licensing at WARF. 'Encouraging preclinical data suggest that ART-101 could help increase lifespan and be more effective in treating prostate cancer than current therapies. We're pleased to partner with Archeus Technologies to continue the development of this innovative asset and look forward to better understanding its role to potentially improve outcomes for prostate cancer patients.'
ART-101 is compatible with multiple therapeutic isotopes, including actinium-225, lutetium-177 and terbium-161. When paired with these isotopes, preclinical data show that ART-101 provides significant potential benefit that could lead to improved outcomes for prostate cancer patients.
About Archeus Technologies
Archeus Technologies is a company developing differentiated radiopharmaceutical therapies for some of the most difficult-to-treat cancers. Starting with its Phase 1-ready therapeutic candidate, ARC-706, the company has assembled a growing pipeline of novel radiopharmaceutical therapy agents and companion diagnostic assets with the potential to provide curative responses to patients with advanced disease. Archeus is led by an executive team with proven radiopharmaceutical expertise and a demonstrated record of advancing innovative agents from discovery through clinical development. In addition, Archeus has a long-standing strategic collaboration with the University of Wisconsin-Madison (UW), a global leader in radiopharmaceuticals and theranostics. To learn more, visit ArcheusTech.com.
About WARF
Celebrating a century of service in 1925, the Wisconsin Alumni Research Foundation (WARF) patents and licenses discoveries from UW-Madison research, manages an investment portfolio generated from licensing and investment proceeds, and provides annual grants to the University of Wisconsin-Madison and the Morgridge Institute for Research to support further scientific investigation and research. By driving collaborations among researchers, investors, industry and entrepreneurs, WARF commercializes innovations from campus through various initiatives. WARF Accelerator improves the commercialization potential of university intellectual property through industry engagement and investment in proof-of-concept milestones to validate market potential, demonstrate commercial value and de-risk technology. WARF Therapeutics partners with UW-Madison and Morgridge Institute researchers employing an industry-focused approach to improve the value propositions of drug candidates. WARF Ventures is an early-stage venture fund that invests in startups based on UW/WARF technologies. Learn more at warf.org.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Newsweek
5 hours ago
- Newsweek
FDA Issues Risk Warning After Mushrooms Recalled Nationwide
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Food and Drug Administration (FDA) has issued a national advisory and classified a recent mushroom recall as Class I, the agency's highest level risk designation, due to potential Listeria monocytogenes contamination. Newsweek contacted Hofood99 Inc via telephone for comment outside of usual working hours on Sunday and left a voicemail message. Why It Matters The Class I recall status indicates that the product poses a risk of causing serious health consequences or death if consumed. Listeria monocytogenes can lead to severe and sometimes fatal infections, especially during pregnancy, and for newborns, elderly adults, and people with weakened immune systems. Although no illnesses have been reported, the risk to public health is significant, prompting the warnings from the FDA. This incident highlights ongoing concerns surrounding food safety, especially in the distribution and handling of perishable produce. What to Know As reported by Newsweek, the firm-initiated recall affects enoki mushrooms distributed by Hofood99 Inc, located at 21903 56th Avenue Oakland Gardens, New York, 11364. The affected mushrooms were sold in 200‑gram green plastic bags and marked with UPC 6 976532 310051 on the back label; a picture of enoki mushrooms is outlined in green on the front of the package. The recall number is H-0261-2025. Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) The 90 boxes of affected product were shipped to retailers nationwide and tested positive for Listeria during routine sampling conducted by the Michigan Department of Agriculture. Consumers are advised not to eat the product and to either discard it or return it to the store where it was purchased for a full refund. Symptoms of Listeria infection may include high fever, muscle aches, nausea, diarrhoea, and in severe cases, complications such as meningitis or miscarriage. Consumers are advised to clean and sanitise refrigerators and any surfaces that may have come into contact with the recalled mushrooms, as the bacteria can survive and spread in cold environments. What People Are Saying The FDA in the original alert in part: "The contamination was discovered after samples were collected from a store in Michigan and subsequent analysis by Michigan Department of Agriculture & Rural Development (MDARD) Laboratory Division revealed the presence of Listeria monocytogenes." The FDA, as stated on its website: "A recall is a method of removing or correcting products that are in violation of laws administered by the Food and Drug Administration (FDA). Recall is a voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective. What Happens Next Consumers with questions can contact Hofood99 Inc. at (917) 756‑9833 during business hours of 9:00 a.m. to 2:00 p.m., Monday to Friday. Further updates are available on the FDA's website. Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts.
Yahoo
7 hours ago
- Yahoo
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
Atai Life Sciences N.V. (NASDAQ:ATAI) is among the . Aegis Capital analysts have reaffirmed their Buy rating on Atai Life Sciences N.V. (NASDAQ:ATAI), with an unchanged price target of $8.00, following the favorable Phase 2b results of the BPL-003 treatment for the company's Treatment Resistant Depression (TRD). Around 193 depression patients, who didn't respond to previous treatment, were part of the Phase 2b trial testing three doses: 0.3 mg, 8 mg, and 12 mg. Not only the 8mg but also the 12mg dose showcased statistically significant improvement in an FDA-accepted measurement of depression, with a healthy side-effect profile. A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. The research firm believes these robust results strengthen the company's efforts to proceed to a Phase 3 clinical program, which would result in marketing approval. Going forward, Atai Life Sciences N.V. (NASDAQ:ATAI) plans to schedule a post-Phase 2 meeting with the FDA, with the Phase 3 trial expected to begin only at the end of the upcoming year. Another noteworthy development is the company's recent $50 million private capital raise, which involved the sale of 18,264,840 common shares with 25% warrant coverage at the market price. Moves like these highlight Atai Life Sciences N.V. (NASDAQ:ATAI)'s capacity to raise cash when needed. Atai Life Sciences N.V. (NASDAQ:ATAI) is a German clinical-stage biopharmaceutical company that researches, develops, and markets mental health treatments in the United States, Germany, and Canada. With a market capitalization of $587.639 million, the company is committed to healing mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
Business Upturn
13 hours ago
- Business Upturn
OPTO Miner launches new mobile app, allowing everyone to mine Bitcoin and Dogecoin for free
Aberdeen, United Kingdom, July 12, 2025 (GLOBE NEWSWIRE) — OPTO Miner, a UK-based cloud mining platform, has recently launched a new mobile app designed for users who want to participate in cryptocurrency mining. Without any hardware equipment or technical background, users can start their mining journey for free and quickly obtain daily income. OPTO Miner is headquartered in the UK and supports a variety of mainstream cryptocurrencies including Bitcoin (BTC), Dogecoin (DOGE) and Litecoin (LTC), and is committed to providing safe and convenient cloud mining services to users around the world. Now, you can check the mining progress, manage contracts, and adjust settings anytime and anywhere by just picking up your phone. Whether you are commuting or taking a break at lunch, mining can run automatically in the background, truly achieving zero intervention and continuous income. The person in charge of the platform said that the original intention of launching this App was to allow more ordinary people to participate in crypto mining, so that it would no longer be a field that only professionals could enter. Five highlights of OPTO Miner App: A truly mobile cloud mining experience The simple and intuitive interface design allows you to monitor your earnings and manage contracts at any time, making it easier to operate than a trading platform. Supports recharge and settlement of more than ten mainstream crypto assets including Bitcoin (BTC), Ethereum (ETH), Dogecoin (DOGE), Ripple (XRP), USDT, etc. Professional-level security The application has built-in McAfee® and Cloudflare® security protection, and data transmission and asset operations are fully encrypted to ensure the safety of funds. Sign up and get bonus、 New users can get a $15 bonus when they register, and they can get a $0.60 incentive for logging in daily, so you can really earn while using it. Diversified contract options Whether it is a $15 short-term contract or a long-term holding plan, there is always one suitable for you. Flexible choice, easy configuration. All-weather stable operation and technical support The App achieves 100% uptime, and users can contact the technical team at any time if they encounter any problems, ensuring worry-free operation. As cryptocurrencies such as Bitcoin, Dogecoin, Litecoin and even XRP become more and more mature, more and more investors are looking for easier and more reliable ways to participate. OPTO Miner launched this app in line with this trend, hoping that everyone can 'move their fingers' to open a new path to passive income. Start using OPTO Miner in just three steps: Step 1: Download the OPTO Miner App Step 2: Register and receive rewards New users will automatically receive a $15 free computing power reward after registration. Step 3: Choose the right contract and start daily mining income Flexible configuration from short-term to long-term contracts, and daily income is automatically settled to the account. OPTO Mienr popular contracts: 【BTC (Miner-S19k-Pro)】Investment amount: $100, contract period: 2 days, daily income: $4, expiration income: $100 + $8 【BTC (AVALON MINER A1326-109T)】Investment amount: $500, contract period: 6 days, daily income: $6.05, expiration income: $500 + $36.3 【BTC (iBeLink BM-K1+)】Investment amount: $1,000, contract period: 10 days, daily income: $12.5, expiration income: $1,000 + $125 【DOGE/LTC (Gold Shell Mini Dog 2)】Investment amount: $3,000, contract period: 20 days, daily income: $41.1, expiration income: $3,000 + $822 【Antminer S17 Pro】Investment amount: $5,000, contract period: 26 days, daily income: $70, maturity income: $5,000 + $1,820 【Avalon A1466】Investment amount: $10,000, contract period: 37 days, daily income: $156, maturity income: $10,000 + $5,772 For more details, please visit the official website: Click me for app download About OPTO Miner Founded in 2018 and headquartered in the UK, OPTO Miner is a global cloud mining platform that is government-certified and financially regulated. Relying on a strong technical team and a global network of mining farms, we are committed to providing users with simple, secure and transparent cryptocurrency mining services. At present, the platform business has covered more than 180 countries and regions around the world, with more than 7 million registered users, and has efficient and stable mining network infrastructure in the United States, the United Kingdom, Canada, the United Arab Emirates, Kazakhstan and other places. With the official launch of the official App, users can participate in mining, manage contracts and view income in real time anytime and anywhere with just a mobile phone without computers or professional knowledge. We always adhere to compliant operations and are committed to allowing more users to easily start a stable and continuous passive income path. Disclaimer: The information provided in this press release does not constitute an investment solicitation, nor does it constitute investment advice, financial advice, or trading recommendations. Cryptocurrency mining and staking involve risks and the possibility of losing funds. It is strongly recommended that you perform due diligence before investing or trading in cryptocurrencies and securities, including consulting a professional financial advisor. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
